home All News open_in_new Full Article

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI

OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) — OBI Pharma, Inc. (“OBI”), a clinical stage oncology company(4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-902, to conduct a Phase 1/2 study. […]


today 7 h. ago attach_file Other

attach_file Society
attach_file Other
attach_file Economics
attach_file Culture
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Economics
attach_file Economics
attach_file Other
attach_file Other
attach_file Economics
attach_file Culture
attach_file Culture
attach_file Transport
attach_file Economics
attach_file Other
attach_file Events


ID: 1970726533
Add Watch Country

arrow_drop_down